This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
New test panel follows a Quest Diagnostics Health Trends® study with the CDC that revealed less than half of pregnant people are screened for hepatitis C as recommended under guidelines SECAUCUS,...
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share,...
DALLAS, August 5, 2022 — The American Heart Association, the world’s leading nonprofit organization focused on longer, healthier lives for all, is committed to addressing the lack of diversity...
Better healthcare among America's large and growing Hispanic community is receiving an important, new level of support from Quest Diagnostics, the world's leading provider of diagnostic...
SECAUCUS, N.J., (August 3, 2022) - Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been recognized by Forbes as one of America’s...
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2022 Disability Equality Index® (DEI) Best Places to Work for...
Analysis of nearly 23 million lab tests finds only 1 in 3 patients with latent tuberculosis were also tested for chronic hepatitis B, despite similar risk factors in patients Findings heighten...
Second quarter revenues of $2.45 billion, down 3.8% from 2021 Second quarter reported diluted earnings per share ("EPS") of $1.96, down 60.5% from 2021; and adjusted diluted EPS of $2.36, down...
PHILADELPHIA & SECAUCUS, N.J.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) today announced it is collaborating with Quest Diagnostics (NYSE: DGX) to provide access to quality, COVID-19 molecular testing...
Company to be able to perform approximately 30,000 tests a week by the end of July, supplementing public health response Physicians can order the novel Quest Diagnostics lab test beginning today...